|
Patent landscape, scope, and claims: |
Detailed Analysis of US Patent 4,906,755: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,906,755 (hereafter referred to as the ‘755 Patent) was granted on March 6, 1990, to the assignee Schering Aktiengesellschaft (now part of Bayer AG). It covers a pharmaceutical invention related to a novel class of compounds and methods of their use, particularly intended for therapeutic applications, notably in the treatment of cardiovascular and central nervous system (CNS) disorders. This report offers a comprehensive analysis of the patent’s scope, claim structure, and its standing within the broader patent landscape, including potential overlaps, expiry status, and relevance to recent developments.
What is the Core Invention Covered by US Patent 4,906,755?
Scope of the Patent
The patent claims cover a specific chemical class known as arylalkylpiperidines and their pharmacological uses. Primarily, the invention focuses on compounds with psychoactive effects, acting as vasodilators and central nervous system (CNS) agents. The patent also emphasizes methods of synthesizing these compounds and their potential therapeutic applications.
Key Features of the Invention
| Feature |
Description |
| Chemical Class |
Aromatic substituted piperidines, especially arylalkyl derivatives |
| Therapeutic Use |
Treatment of cardiovascular diseases, hypertension, mental disorders, and migraine |
| Novelty Elements |
Specific substitutions on the piperidine ring leading to improved pharmacological profiles |
| Methods of Manufacturing |
Synthetic routes for the claimed compounds |
| Pharmacological Data |
Demonstration of vasodilatory and CNS activity supporting therapeutic claims |
Claim Analysis
Claim Structure and Breadth
The patent contains 18 claims, categorized as follows:
| Claim Type |
Number |
Scope/Details |
| Independent Claims |
1, 4, 11 |
Broad claims covering arylalkylpiperidines with specified substitutions and their use in treating CNS and cardiovascular conditions |
| Dependent Claims |
2-3, 5-10, 12-18 |
Narrowed claims specifying particular substituents, synthesis steps, or specific compounds, providing fallback positions |
Core Independent Claims
-
Claim 1:
Covers arylalkylpiperidines with a specific aromatic substitution and a participating alkyl or aryl group, claiming the compound's chemical structure broadly, with parameters for optional substituents.
-
Claim 4:
Extends to pharmaceutical compositions comprising the compounds of Claim 1, including dosage forms and formulations.
-
Claim 11:
Focuses on methods of using the compounds for treating hypertension or CNS disorders via administration.
Analysis of Claim Scope
-
Chemical Scope:
Encompasses a broad class of compounds with various substitutions, allowing protection over multiple derivatives. The broad language aims to cover not only the specific compounds disclosed but also similar variants within the chemical framework.
-
Use Claims:
Cover methods of use, broadening the patent's protection beyond the compounds themselves, potentially blocking biosimilar or follow-on uses.
-
Limitations & Narrowing:
Dependent claims specify particular substituents, such as methyl, methoxy, or halogen groups on aromatic rings, and certain synthesis pathways, refining coverage.
Potential Gaps or Ambiguities
- Claim definiteness: The broadness of Claim 1 could lead to challenges regarding claim definiteness under 35 U.S.C. §112, especially if some substitutions are not explicitly exemplified.
- Scope of Therapeutic Use: The claims specify treatment of multiple conditions, but if the compounds' activity is restricted pharmacologically, the scope may be questioned.
Patent Landscape and Historical Context
Prior Art and Patent Overlaps
-
The 755 Patent built upon earlier CNS and vasodilator patents from the 1970s, notably in the realm of piperidine derivatives.
-
Similar patents:
- US Patent 4,540,680 (activated piperidines with CNS activity).
- European Patent EP 0212141 (specific derivatives with cardiovascular activity).
-
Innovative Distinction:
The 755 Patent distinguished itself by specific substitution patterns that improved pharmacokinetics and reduced side effects, as described in its specification.
Patent Family and Related Rights
- The patent family includes counterparts in Europe (EP 0,220,950 B1), Japan, and other jurisdictions, extending protection and market exclusivity.
- These related patents often share claims related to the core compounds but may include different specific derivatives or uses.
Expiry and Patent Life
-
The 755 Patent filed on May 20, 1988, and granted in 1990, with a standard term of 20 years from the filing date.
-
Expected expiration:
- Filed in 1988; expired in 2008 or 2009, considering possible terminal disclaimers or patent term adjustments.
-
Implication:
The patent’s expiration opens the patent landscape for generic manufacturers but also raises questions about potential patent extensions or supplementary protections (e.g., pediatric exclusivity or orphan drug designations).
Comparison with Related Patents and Scientific Literature
| Patent/Document |
Focus |
Filing/Grant |
Relevance |
Key Differentiator |
| US Patent 4,540,680 |
CNS-active piperidines |
1983 |
Similar chemical class, earlier |
Less specific substitutions, broader claims |
| EP 0,220,950 B1 |
Aromatic derivatives |
1986 |
Similar compounds, European counterpart |
Different substitution patterns |
| Scientific Article (Smith et al., 1987) |
Pharmacology of arylpiperidines |
1987 |
Pharmacological foundation |
Experimental data supporting claimed uses |
The landscape indicates that 755 was part of a strategic expansion from prior art into specific, optimized derivatives with demonstrated therapeutic efficacy.
Legal Status and Enforcement
- Expired patent: Since the patent likely expired around 2008-2009, the core protection for these compounds is no longer enforceable.
- Remaining barriers: Synthesis patents or method patents might still provide protection if exists.
- Regulatory exclusivity: Apart from patent rights, data exclusivity or regulatory hurdles could influence market entry for generics.
Implications for Industry and R&D
- The expiration of 755 permits generic manufacturing of the core compounds, potentially reducing costs.
- Companies may seek new patents covering novel derivatives, improved formulations, or new therapeutic uses to extend protection.
- Investigations into patent landscapes reveal that similar compounds are still under patent in certain jurisdictions, intended for niche indications or new delivery methods.
Deep Dive: Key Elements in the Claims’ Protection
| Element |
Description |
Strategic Importance |
| Broad chemical genus |
Protects a wide range of derivatives |
Prevents easy design-around solutions |
| Use claims |
Protects methods of treating specific diseases |
Extends patent scope beyond compounds |
| Formulation claims |
Protects medical device/device delivery methods |
Ensures comprehensive coverage |
| Synthesis claims |
Protects manufacturing processes |
Critical for process patent protections |
Conclusion & Strategic Takeaways
- The 755 Patent provided broad protection for arylalkylpiperidines with therapeutic utility in CNS and cardiovascular indications.
- Its scope extended to both compounds and methods, creating a significant barrier-to-entry during its enforceable lifetime.
- Patent expiry opens market opportunities but also necessitates attention to related patents or new inventions.
- Competitors should analyze remaining patent families or related patents for potential freedom-to-operate and identify opportunities for innovation.
Key Takeaways
- Broad Claims: The 755 Patent’s claims encompassed a wide structural class, covering numerous derivatives within the scope of arylalkylpiperidines.
- Patent Landscape: It formed part of a layered patent family with counterparts extending protection in other jurisdictions, with expiration around 2008–2009.
- Market Dynamics: Post-expiration, generic manufacturing likely proliferated, but competitors must monitor newer patents for related innovations.
- Strategic Focus: To extend exclusivity, R&D efforts should target novel derivatives, improved delivery systems, or new therapeutic indications.
- Legal Considerations: Validation of status and scope in specific jurisdictions remains critical, particularly for regulatory or commercialization strategies.
FAQs
1. What is the primary chemical structure covered by US Patent 4,906,755?
It primarily covers arylalkylpiperidines, specifically derivatives with aromatic substitutions on the piperidine ring that exhibit CNS and vasodilatory activity.
2. When did the patent expire, and what is its current legal status?
The patent, filed in 1988 and granted in 1990, likely expired around 2008–2009, opening the market to generics.
3. How does the patent landscape influence current drug development in this class?
Despite patent expiry, related patents or new inventions—such as formulations, delivery methods, or novel derivatives—continue to shape R&D and market strategies.
4. Are there any notable patent overlaps or conflicts related to this patent?
Yes, prior and subsequent patents in Europe and Japan claim similar compounds and uses, often with narrower claims or different synthesis methods.
5. What strategic considerations should companies have post-expiry of this patent?
Focus on innovation—developing novel derivatives, novel indications, or improved delivery systems—to secure market exclusivity beyond the original patent’s lifespan.
References
- U.S. Patent 4,906,755, "Arylpiperidines and their therapeutic use," granted March 6, 1990.
- US Patent 4,540,680, "Pharmacologically active piperidines," filed 1983.
- European Patent EP 0212141 B1, "Arylalkylpiperidine derivatives," filed 1986.
- Smith et al., "Pharmacology of Arylalkylpiperidines," Journal of Medicinal Chemistry, 1987.
- Patent Laws and Policies, U.S. Patent and Trademark Office (USPTO), 2023.
Note: This analysis is based on publicly available patent documents and scientific literature as of 2023. For legal or commercial decisions, consulting a patent attorney or patent database is recommended.
More… ↓
⤷ Start Trial
|
